SCHEMBL3093497

SCHEMBL3093497

Cc1ccc2c(c1F)NC(=O)C2=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.56
CES1 P23141 9/20 0.53
BCHE P06276 2/20 0.43
NSD2 O96028 2/20 0.43
TGM2 P21980 2/20 0.43
ALDH1A1 P00352 1/20 0.41
ALDH2 P05091 1/20 0.41
ALDH3A1 P30838 1/20 0.41
LIG1 P18858 1/20 0.40
CASP3 P42574 1/20 0.36
CASP2 P42575 1/20 0.36
CASP7 P55210 1/20 0.36
CASP6 P55212 1/20 0.36
CASP8 Q14790 1/20 0.36
TDP2 O95551 1/20 0.36
HSP90AA1 P07900 1/20 0.36
PAX8 Q06710 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2892415 0.80 CES1 (0.67) DAOCES1BCHENSD2TGM2
SCHEMBL3076875 0.80 CES1 (0.50) DAOCES1BCHENSD2TGM2
SCHEMBL3080757 0.77 CES1 (0.67) DAOCES1BCHENSD2TGM2
SCHEMBL3096093 0.77 DAO (0.56) DAOCES1BCHENSD2TGM2
SCHEMBL2373643 0.77 CES1 (0.47) DAOCES1BCHENSD2TGM2
SCHEMBL14358786 0.77 CES1 (0.67) DAOCES1BCHENSD2TGM2
SCHEMBL3085898 0.77 CES1 (0.62) DAOCES1BCHENSD2TGM2
SCHEMBL4363644 0.74 DAO (0.53) DAOCES1BCHENSD2TGM2
SCHEMBL3334809 0.73 CES1 (0.62) DAOCES1BCHENSD2TGM2
SCHEMBL31483785 0.73 CES1 (0.62) DAOCES1BCHENSD2TGM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024175114-A1 BORON CONTAINING COMPOUNDS AND THERAPEUTIC USES THEREOF Shanghai Yuyao Biotech Ltd. (CN) 2024-08-29 WO disclosed
US-7829567-B2 Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same KAOHSIUNG MEDICAL UNIVERSITY (TW) 2010-11-09 US disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
EP-2139856-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS Topotarget A/S (DK) 2010-01-06 EP disclosed
US-20090111987-A1 Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same KAOHSIUNG MEDICAL UNIVERSITY (TW) 2009-04-30 US disclosed
WO-2008129075-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS TOPOTARGET A/S (DK) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111987-A1 Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same IMPA1, IMPDH1, IPO5 DAO 3171/4885CES1 2260/4885BCHE 3561/4885
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TPH2, TPH1, HTR2C DAO 1360/4885CES1 3688/4885BCHE 3124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.